Dave Carlucci Chairman and CEO IMS Health
|
|
- Dora Gibbs
- 5 years ago
- Views:
Transcription
1 Dave Carlucci Chairman and CEO IMS Health 1 March 11, 2009
2 Safe Harbor Certain statements we make today are forward-looking within the meaning of the US federal securities laws. These statements include, certain projections regarding the trends in our business, future events and future financial performance. We would like to caution you that these statements are just predictions, and the actual event or results may differ. They can be affected by inaccurate assumptions or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. We call your attention to our fourth quarter 2008 earnings release and our 2008 full year report on Form 10-K, which set forth important factors that could cause actual results to differ materially from those contained in any such forward-looking statements. All forward-looking statements represent our views only as of the date they are made and the company undertakes no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. 2
3 Statement on Guidance We guide to constant dollar revenue but GAAP reported revenue will include the effect of foreign currency fluctuations, which we cannot at this time reliably predict. Non-GAAP Free cash flow guidance may differ from net cash provided by operating activities on a GAAP basis in ways similar to those described in the reconciliations identified in the 2008 free cash flow reconciliation which can be found in the Investors Section of and attached to this document. Statements relating to guidance are based on current expectations as of March 11, These statements are forward-looking, and actual results may differ materially. IMS does not undertake to update these targets in any way or for any reason prior to discussing actual results. 3
4 Financial Highlights Today we will discuss certain measures on a non-gaap basis. The non-gaap measures discussed today are those used by management for the purposes of global business decision-making, including developing budgets and managing expenditures. These non-gaap measures exclude certain U.S. GAAP measures to the extent that management believes exclusion will facilitate comparisons across periods and more clearly indicate trends. Any such measures are not prepared under a comprehensive set of accounting rules and are not a replacement for the more comprehensive information for investors included in IMS's U.S. GAAP results. The method IMS uses to prepare these measures differs in significant respects from U.S. GAAP and is likely to differ from the methods used by other companies. Investors interested in management's non-gaap measures are urged to review the reconciliations of the adjusted measures to comparable U.S. GAAP results. Preliminary (non-gaap) 2008 Free Cash Flow and a complete reconciliation to the comparable GAAP numbers can be found in the Investors Section of and are attached to this document. 4
5 IMS: The gold standard for information about the pharmaceutical and healthcare industries Global leader in market intelligence with more than five decades of experience Diverse sources of revenue in over 100 countries Expanding across new client sets in high growth business areas Growing market opportunity greater than $7 billion Financially strong and investing for growth 5 5
6 From 2002, our addressable market opportunity has expanded more than three times Global Measurement Performance Mgmt Pricing and Market Access Managed Care Contracting Government Health Economics & Outcomes Research Promotional Mgmt $2 Billion 2002 Consulting New Audiences New Businesses Sales Force Effectiveness Market Research Information Mgmt Sales Management Generics Biotech Oncology Portfolio Strategy $7+ Billion
7 We have delivered excellent performance over the last four years Revenue $M Operating Income* $M $2,400 $2,200 $2,000 $1,800 $1, $500 $450 $ Earnings per share* Free Cash Flow per share* $1.70 $1.60 $1.40 $ $1.50 $ * Non-GAAP, 2005 excludes FAS 123r expense
8 Our strong cash flow and capital allocation reflects the importance of investing in our business and returning cash to shareholders $1,200 $1,000 $800 $600 $400 $200 M Share Repurchase Cap Ex/Software Acquisitions $1.2 billion cash flow generated : $439 million acquisitions $524 million new offerings & capital expenditures $1.8 billion share repurchase $
9 Full Year 2008 Adjusted (Non-GAAP) Results Executing well in a challenging environment $ Millions Full Year 2008 Revenue $2,330 Operating Income $511 Margin 22% Net Income $312 EPS $1.70 Year-to-Year Growth 6% 6% Flat 2% 11% Preliminary Free Cash Flow $317 10% 9
10 2008 Performance Summary Executing well in a dynamic environment Free cash flow strong: $317M +10% Adjusted operating margin: 22%, flat year-to-year Adjusted EPS: $ % Restructuring plan completed Disciplined approach to capital deployment Excellent liquidity position Improving our productivity and investing in new business growth areas 10
11 In 2009 our clients face both challenges and opportunities Continuing to optimize near-term results Selecting growth opportunities more decisively geographies, portfolios, launches Accelerating implementation of new business models Account for pending losses from patent expiries Prepare for a new wave of innovation Adjust for the economic downturn 2009 Pharmaceutical Market Summary 4.5% to 5.5% growth Emerging markets & specialty medicines drive growth ~$24 billion in patent expiries More pressure from payers to prove value 11
12 In 2009 our operational roadmap is clear Managing our portfolio to growth opportunities Capitalize on our leadership position in patient/payer insights Leverage global expertise in new commercial models Expand our launch readiness capabilities Accelerate expansion in implementation services Prioritizing our regional investments Extend our strength in emerging / mid-markets Improve growth in the major markets Optimizing our client engagements Execute on unique strategies for each large client Increase penetration for mid-sized clients Aggressively engaging new audiences Governments, payers, generics, consumer health Leveraging our productivity investments 12
13 In 2009 our operational roadmap is clear Managing our portfolio to growth opportunities Capitalize on our leadership position in patient/payer insights Leverage global expertise in new commercial models Expand our launch readiness capabilities Accelerate expansion in implementation services Prioritizing our regional investments Extend our strength in emerging / mid-markets Improve growth in the major markets Optimizing our client engagements Execute on unique strategies for each large client Increase penetration for mid-sized clients Aggressively engaging new audiences Governments, payers, generics, consumer health Leveraging our productivity investments 2009 Guidance CD revenue growth 0 3% EPS $ $1.77 Free cash flow at or above the 2008 level of $317M 13
14 Investment Summary Global leader well positioned for a dynamic environment Invested ahead of market trends Substantially differentiated global capabilities Capitalizing on high growth areas across several dimensions Client: governments, payers, generics, consumer health Geographic: emerging & mid-markets Offerings: patient & payer behaviors and specialty markets Services: building momentum in implementation services Financially strong Excellent cash flow generation Strong liquidity position Improving our productivity 14
15 15
16 News For Immediate Release Contacts: Darcie Peck Gary Gatyas Investor Relations Communications (203) (610) IMS Health Reports 2008 Fourth-Quarter and Full-Year Results Delivers Strong Earnings Per Share Growth, Exceptional Cash Flow Performance NORWALK, CT, February 5, 2009 IMS Health (NYSE: RX), the world s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced fourth-quarter 2008 net income of $98.5 million and diluted earnings per share of $0.54, compared with net income of $18.0 million and EPS of $0.09 in the fourth quarter of After adjusting for a 2007 restructuring charge and certain other items, net income on a non-gaap basis for the fourth quarter of 2008 rose 9 percent and EPS on a non-gaap basis was up 16 percent year over year (See below and Note c to the financial tables). Total revenue for the fourth quarter of 2008 was $580.9 million, a 4 percent decrease or flat constant dollar from the fourth quarter of For full-year 2008, net income was $311.3 million and EPS was $1.70, up 33 percent and 44 percent, respectively. After adjusting for certain items, net income on a non-gaap basis grew 2 percent and EPS on a non-gaap basis rose 11 percent for the year (See below and Note c to the financial tables). Revenue for the 2008 full year was $2,329.5 million, up 6 percent or 3 percent constant dollar from 2007.
17 IMS delivered exceptional cash flow and double-digit earnings per share growth in 2008, reflecting the strength of our financial position and soundness of our strategy, said David R. Carlucci, IMS chairman and chief executive officer. We have positioned IMS to perform well in a slower growth environment and taken the right steps to align for new opportunities, tightly manage our costs, and maintain a solid balance sheet. As the industry leader, we are becoming an even stronger, more vital partner to clients right at the center of helping them adapt to today s market realities. The company also announced its financial guidance for the 2009 full year. Constant-dollar revenue growth is expected to be flat to 3 percent this year, and diluted earnings per share is expected to be in the $1.70 $1.77 range. Operating income in the fourth quarter of 2008 was $126.6 million, compared with $47.0 million in the year-earlier quarter. When adjusted for non-cash asset write-downs in 2008, operating income on a non-gaap basis for the 2008 fourth quarter was $136.0 million compared with $135.7 million in the year-earlier quarter after adjusting for the 2007 restructuring charge (See Note c to the financial tables). Fourth-quarter 2008 diluted earnings per share was $0.54 on a GAAP basis, compared with $0.09 in the prior-year quarter. When adjusted for certain items, earnings per share on a non-gaap basis for this year s fourth quarter grew $0.07 year over year, to $0.50 (See Note c to the financial tables). Net income on a GAAP basis was $98.5 million, compared with $18.0 million in the year-earlier quarter. When adjusted for certain items, net income on a non-gaap basis for the 2008 fourth quarter was $90.6 million, compared with $83.4 million in the fourth quarter of 2007 (See Note c to the financial tables). Full-Year Results For the 2008 full year, revenues were $2,329.5 million, up 6 percent or 3 percent constant dollar, compared with revenue of $2,192.6 million in Operating income for Page 2
18 2008 was $498.3 million, compared with $393.3 million in the year-earlier period, up 27 percent and 18 percent constant dollar. After adjusting for a 2008 charge related to the company s Government Solutions subsidiary and 2008 non-cash asset write-downs, operating income on a non-gaap basis for the 2008 full year was $511.5 million, up 6 percent or flat on a constant-dollar basis compared with operating income on a non-gaap basis of $482.0 million in 2007, which reflects an adjustment for the 2007 restructuring charge (See Note c to the financial tables). For the 2008 full year, diluted earnings per share on a GAAP basis was $1.70, compared with $1.18 a year earlier. After adjusting for certain items, earnings per share for 2008 on a non-gaap basis was $1.70, $0.17 above diluted earnings per share on a non-gaap basis of $1.53 in 2007 (See Note c to the financial tables). Net income on a GAAP basis was $311.3 million, compared with $234.0 million in When adjusted for certain items, net income for 2008 on a non-gaap basis was $311.7 million, compared with $304.3 million in the year-earlier period (See Note c to the financial tables). Preliminary net cash provided by operating activities on a GAAP basis for 2008 was $420.7 million preliminary free cash flow on a non-gaap basis was $317.5 million (See Note d to the financial tables). Balance Sheet Highlights IMS s cash and cash equivalents as of December 31, 2008 totaled $215.7 million, compared with $218.2 million on December 31, Total debt as of December 31, 2008 was $1,404.2 million, up from $1,203.2 million at the end of 2007, primarily due to the impact of exchange rates on foreign debt. Share Repurchase Program, Shares Outstanding During the fourth quarter, approximately 440,000 shares were repurchased at a total cost of $7.6 million. Shares repurchased in 2008 totaled 10.5 million shares at a cost Page 3
19 of $238.0 million. The impact of the share repurchase program was an EPS benefit of $0.06 per share in 2008 compared to $0.01 per share in The number of shares outstanding as of December 31, 2008 was approximately million, compared with million as of December 31, About IMS Operating in more than 100 countries, IMS Health is the world s leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.3 billion in 2008 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional information is available at Conference Call and Webcast Details IMS will host a conference call at 8:00 a.m. ET today to discuss its fourth-quarter and full-year results. To participate, please dial 1 (800) (U.S. and Canada) or 1 (212) (outside the U.S. and Canada) approximately 15 minutes before the scheduled start of the call. The conference call also will be accessible live on the Investor Relations section of the IMS Website at Prior to the conference call, a copy of this press release and any other financial or statistical information presented during the call will be made available in the Investors area of IMS s Website. A replay of the conference call will be available online on the Investors section of the IMS Website and via telephone by dialing 1 (800) (U.S. and Canada) or 1 (402) (outside the U.S. and Canada), and entering access code beginning at 10:30 a.m. ET today. Page 4
20 Forward-Looking Statements This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of Although IMS Health believes the expectations contained in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This information may involve risks and uncertainties that could cause actual results of IMS Health to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to (i) regulatory, legislative and enforcement initiatives, particularly in the areas of data access and utilization and tax, (ii) the risks associated with operating on a global basis, including fluctuations in the value of foreign currencies relative to the U.S. dollar, and the ability to successfully hedge such risks, (iii) to the extent unforeseen cash needs arise, the ability to obtain financing on favorable terms, (iv) to the extent IMS Health seeks growth through acquisitions and joint ventures, the ability to identify, consummate and integrate acquisitions and joint ventures on satisfactory terms, (v) the ability to develop new or advanced technologies and systems for its businesses on time and on a cost-effective basis, and (vi) deterioration in economic conditions, particularly in the pharmaceutical, healthcare or other industries in which IMS Health s customers operate. Additional information on factors that may affect the business and financial results of the company can be found in the filings of the company made from time to time with the Securities and Exchange Commission. IMS Health undertakes no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. Page 5
21 Table 1 IMS Health GAAP Income Statement Three Months Ended December 31 (unaudited, in millions except per share) 2008 GAAP 2007 GAAP % Fav (Unfav) Non-GAAP Constant $ Growth % Revenue (a) (b) Sales Force Effectiveness $262.2 $272.5 (4) % 0 Portfolio Optimization (6) (1) Launch, Brand and Other (3) 3 Total (4) 0 Revenue Detail: Information & Analytics ( I&A ) Revenue (5) 0 Consulting & Services ( C&S ) Revenue (3) 2 Total Revenue (4) 0 Operating Expenses (b) Operating Costs of I&A (180.0) (187.7) 4 Direct and Incremental Costs of C&S (72.4) (74.2) 2 Selling and Administrative (157.8) (175.5) 10 External-use Software Amortization (11.7) (12.8) 9 Depreciation and Other Amortization (23.0) (20.1) (14) Severance, impairment, and other charges (9.4) (88.7) 89 Total (454.4) (559.0) 19 Operating Income (a) % 161 Interest expense, net (7.8) (7.3) (6) Other Income (Expense), net (15.5) (3.9) NM Pretax Income Provision for Income Taxes (4.8) (17.8) 73 Net Income (c) NM Diluted EPS: Total Diluted EPS $ 0.54 $0.09 NM Shares Outstanding: Weighted Average Diluted End-of-Period Actual Weighted Average Basic The accompanying notes are an integral part of these financial tables. Page 6
22 Table 2 IMS Health GAAP Income Statement Twelve Months Ended December 31 (unaudited, in millions except per share) 2008 GAAP 2007 GAAP % Fav (Unfav) Non-GAAP Constant $ Growth % Revenue (a) (b) Sales Force Effectiveness $1,057.1 $1, % 2 Portfolio Optimization Launch, Brand and Other Total 2, , Revenue Detail: Information & Analytics ( I&A ) Revenue 1, , Consulting & Services ( C&S ) Revenue Total Revenue 2, , Operating Expenses (b) Operating Costs of I&A (756.6) (713.2) (6) Direct and Incremental Costs of C&S (275.5) (244.3) (13) Selling and Administrative (650.3) (626.9) (4) External-use Software Amortization (49.7) (48.6) (2) Depreciation and Other Amortization (89.6) (77.6) (15) Severance, impairment, and other charges (9.4) (88.7) 89 Total (1,831.2) (1,799.3) (2) Operating Income (a) % 18 Interest expense, net (34.5) (29.7) (16) Gains (losses) from investments, net (84) Other Income (Expense), net (49.1) (16.3) (202) Pretax Income Provision for Income Taxes (103.8) (115.6) 10 Net Income (c) Diluted EPS: Total Diluted EPS $ 1.70 $ Shares Outstanding: Weighted Average Diluted End-of-Period Actual Weighted Average Basic The accompanying notes are an integral part of these financial tables. Page 7
23 Table 3 IMS Health Selected Consolidated Balance Sheet Items (unaudited, in millions) Dec. 31, 2008 Dec. 31, 2007 Cash and cash equivalents $215.7 $218.2 Accounts receivable, net Total long-term debt 1, ,203.2 The accompanying notes are an integral part of these financial tables. Page 8
24 Table 4 IMS Health Preliminary GAAP Cash Flows from Operating Activities Twelve Months Ended December 31 (unaudited, in millions) 2008 GAAP Net Income $ Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities: Depreciation & Amortization Bad Debt Expense 2.3 Deferred Income Taxes (11.9) Gain on Sale of Assets, net (4.4) Minority Interests in Net Income of Consolidated Companies 7.7 Non-Cash Stock-Based Compensation Charges 28.0 Net Tax Expense on Stock-Based Compensation (0.5) Excess Tax Benefits from Stock-Based Compensation (0.1) Non-Cash Severance, Impairment & Other Charges 9.4 Change in Assets and Liabilities, Excluding Effects from Acquisitions and Dispositions: Net Decrease in Accounts Receivable 31.9 Net Increase in Work-In-Process Inventory (1.7) Net Increase in Prepaid Expenses & Other Current Assets (0.2) Net Increase in Accounts Payable 1.6 Net Decrease in Accrued & Other Current Liabilities (12.6) Net Decrease in Accrued Severance, Impairment & Other (51.1) Net Decrease in Deferred Revenues (27.7) Net Decrease in Accrued Income Taxes (19.1) Net Decrease in Pension Assets, net of Liabilities 8.4 Net Decrease in Other Long-Term Assets, net of Other Long-Term Liabilities 10.0 Net Cash Provided by Operating Activities (d) $ The accompanying notes are an integral part of these financial tables. Page 9
25 IMS Health NOTES TO FINANCIAL TABLES a) Reference to Constant-Dollar Growth (non-gaap). Constant-dollar growth (non-gaap) rates eliminate the impact of year-over-year foreign currency fluctuations (Tables 1 and 2). IMS reports results in U.S. dollars but does business on a global basis. Exchange rate fluctuations affect the rates at which IMS translates foreign revenues and expenses into U.S. dollars and have important effects on results. In order to illustrate these effects, IMS provides the magnitude of changes in revenues and operating income in constant-dollar terms. IMS uses results at constant-dollar rates for purposes of global business decision-making, including developing budgets and managing expenditures. IMS management believes this information, when read together with U.S. GAAP results, facilitates a comparative view of business growth. Constant-dollar rates are not prepared under U.S. GAAP and are not a replacement for the more comprehensive information for investors included in IMS s U.S. GAAP results. The method IMS uses to prepare constant-dollar rates differs in significant respects from U.S. GAAP and is likely to differ from the methods used by other companies. b) Revenue and operating expenses in 2007 reflect reclassifications to make them comparable with the 2008 presentation. c) Net income, fully diluted EPS and, where applicable, Operating income for the three and twelve months ended December 31, 2008 included the following notable items: In Selling and administrative expenses, $3.7 million of expense ($2.4 million net of taxes, or $0.01 EPS impact for the twelve months ended December 31, 2008) recorded in the three months ended September 30, 2008 related to the Voluntary Disclosure Program at the Company s Government Solutions subsidiary as discussed in Note 7 of the Company s Form 10-Q for the quarterly period ended September 30, In Severance, impairment and other charges, a $9.4 million restructuring charge ($6.9 million net of taxes, or $0.04 EPS impact for the three and twelve months ended December 31, 2008) recorded in the three months ended December 31, 2008 for the write-off of certain capitalized software assets resulting from the discontinuation of certain IMS products at the end of In Other expense, net, a $16.1 million foreign exchange loss ($14.5 million net of taxes, or $0.08 EPS impact for the three and twelve months ended December 31, 2008) related to the liquidation of nonfunctional currency Venezuelan Bolívars held at the Company s Swiss operating subsidiary and a $4.0 million gain ($2.6 million net of taxes, or $0.01 EPS benefit for the three and twelve months ended December 31, 2008) related to the sale of certain assets in the Company s Latin America region, both recorded in the three months ended December 31, In Provision for income taxes, a $20.7 million net tax benefit ($0.11 EPS benefit for the three and twelve months ended December 31, 2008) as a result of a non-u.s. reorganization involving several IMS subsidiaries recorded in the three months ended December 31, Additionally, in Provision for income taxes, a $3.9 million tax phasing adjustment ($0.02 EPS impact) was reflected in the non-gaap measures for the three months ended December 31, 2008 arising from the expiration of both a non- U.S. agreement and certain non-u.s. statutes of limitations. Adjusting for these tax items resulted in an effective tax rate of approximately 29% in the non-gaap measures for the twelve months ended December 31, After adjusting for these items and the phasing of foreign exchange losses ($1.9 million, or $0.01 EPS benefit, net of taxes for the three months ended December 31, 2008), operating income, net income and diluted EPS on a non-gaap basis would have been $136.0 million and $511.5 million, $90.6 million and $311.7 million and $0.50 and $1.70 for the three and twelve months ended December 31, 2008, respectively. Net income, fully diluted EPS and, where applicable, Operating income for the three and twelve months ended December 31, 2007 included the following notable items: In Severance, impairment and other charges, an $88.7 million restructuring charge ($62.6 million net of taxes, or $0.32 EPS impact for the three and twelve months ended December 31, 2007) recorded in the three months ended December 31, 2007 to strengthen client-facing operations worldwide, increase the Company s operating efficiencies and streamline its cost structure in response to healthcare marketplace dynamics. In Provision for income taxes, a $7.5 million tax provision ($0.04 EPS impact for the twelve months ended December 31, 2007) recorded in the three months ended September 30, 2007 to revalue net deferred tax assets in Germany as a result of a reduction in the statutory German federal tax rate during the third quarter of Page 10
26 In Provision for income taxes, a $20.9 million tax benefit during the three months ended March 31, 2007 arising from the settlement of a foreign tax audit and the reorganization of certain subsidiaries. A $5.6 million tax phasing adjustment ($0.03 EPS impact) was reflected in the non-gaap measures for the three months ended December 31, This phasing adjustment, which resulted in an effective tax rate of approximately 31% in the non-gaap measures for the three months ended December 31, 2007, was necessary in order to achieve an effective tax rate of approximately 31% in the non-gaap measures for the twelve months ended December 31, After adjusting for these items and the phasing of foreign exchange losses ($2.8 million, or $0.01 EPS benefit, net of taxes for the three months ended December 31, 2007), operating income, net income and diluted EPS on a non-gaap basis would have been $135.7 million and $482.0 million, $83.4 million and $304.3 million and $0.43 and $1.53 for the three and twelve months ended December 31, 2007, respectively. References are made to results that represent certain U.S. GAAP measures after adjustment to reflect notable items to the extent that management believes adjusting for these items will facilitate better comparisons across periods and more clearly indicate trends. These non-gaap measures are those used by management for purposes of global business decision making, including developing budgets and managing expenditures. Any such measures presented on a non-gaap basis are not prepared under a comprehensive set of accounting rules and are not a replacement for the more comprehensive information for investors included in IMS s U.S. GAAP results. d) Reconciliation of Preliminary GAAP Cash Flows from Operating Activities to Non-GAAP Free Cash Flow Twelve Months Ended December 31 (unaudited, in millions) 2008 Note Reference Net Cash Provided by Operating Activities (unaudited) $ Capital Expenditures (36.4) 2 Additions to Computer Software (77.6) 2 Proceeds from Sale of Assets Deferred Income Taxes Minority Interests in Net Income of Consolidated Companies (7.7) 4 Net Tax Expense on Stock-Based Compensation Excess Tax Benefits from Stock-Based Compensation Net Decrease in Accrued Income Taxes Net Decrease in Pension Assets, net of Liabilities (8.4) 6 Net Decrease in Other Long-Term Assets, net of Other Long-Term Liabilities (10.0) 6 Non-GAAP Free Cash Flow (unaudited) $ Notes: 1 Non-GAAP Free Cash Flow excludes certain amounts to the extent that management believes that exclusion will facilitate comparisons across periods and more clearly indicate trends. Although IMS discloses adjusted Non-GAAP Free Cash Flow in order to give a full picture to investors of the operational performance of its business as seen by management, Non-GAAP Free Cash Flow is not prepared under a comprehensive set of accounting rules and is not a replacement for the more comprehensive information for investors included in IMS's U.S. GAAP results. The method IMS uses to prepare Non-GAAP Free Cash Flow differs in significant respects from U.S. GAAP and is likely to differ from the methods used by other companies. 2 Investments in capital assets and software are integral to the ongoing business and operations of the Company and are therefore included as part of Non-GAAP Free Cash Flow. 3 Movements in deferred and accrued income taxes do not necessarily relate directly to current operations and therefore are excluded from Non-GAAP Free Cash Flow. 4 Non-GAAP Free Cash Flow is designed to only include IMS's share of Net income from consolidated subsidiaries. Page 11
27 5 Tax benefits and expenses from stock-based compensation are excluded from Non-GAAP Free Cash Flow as they are considered to be financing activities. 6 Pension assets and liabilities and other inherently long-term assets and liabilities are not viewed as part of current operations and are therefore excluded from Non-GAAP Free Cash Flow. Amounts presented in the financial tables may not add due to rounding. These financial tables should be read in conjunction with IMS Health s filings previously made or to be made with the Securities and Exchange Commission. Page 12
28 IMS Health Incorporated Reconciliation of GAAP Cash Flow Components to Non-GAAP Free Cash Flow (Unaudited) Twelve Months Ended December 31, 2008 GAAP Non-GAAP Cash Flow Free (In thousands) Components Adjustments Cash Flow 1 Cash Flows from Operating Activities: Net Income $ 311,250 $ - $ 311,250 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 139, ,364 Bad debt expense 2, ,267 Deferred income taxes (11,931) 11, Gain from investments, net (379) 0 (379) Gain on sale of assets, net (4,041) 0 (4,041) Minority interests in net income of consolidated companies 7,702 (7,702) 3 0 Non-cash stock-based compensation charges 28, ,036 Net tax expense on stock-based compensation (499) Excess tax benefits from stock-based compensation (94) Non-cash severance, impairment and other charges 9, ,408 Change in assets and liabilities, excluding effects from acquisitions and dispositions: Net decrease in accounts receivable 31, ,931 Net increase in work-in-process inventory (1,654) 0 (1,654) Net increase in prepaid expenses and other current assets (240) 0 (240) Net increase in accounts payable 1, ,580 Net decrease in accrued and other current liabilities (12,550) 0 (12,550) Net decrease in accrued severance, impairment and other charges (51,057) 0 (51,057) Net decrease in deferred revenues (27,694) 0 (27,694) Net decrease in accrued income taxes (19,064) 19, Net decrease in pension assets, net of liabilities 8,352 (8,352) 5 0 Net decrease in other long-term assets, net of other long-term liabilities 9,967 (9,967) 5 0 Net Cash Provided by Operating Activities $ 420,654 $ 5,567 $ 426,221 Cash Flows (Used in) Provided by Investing Activities: Capital expenditures (36,352) 0 (36,352) 6 Additions to computer software (77,642) 0 (77,642) 6 Proceeds from sale of assets 5, ,272 6 Non-GAAP Free Cash Flow, End of Period $ 317,499 Please see following page for the accompanying notes to the Reconciliation of GAAP Cash Flow Components to Non-GAAP Free Cash Flow (Unaudited).
29 IMS Health Incorporated Notes to Reconciliation of GAAP Cash Flow Components to Non-GAAP Free Cash Flow (Unaudited) (In thousands) Notes: 1 Non-GAAP Free Cash Flow excludes certain amounts to the extent that management believes that exclusion will facilitate comparisons across periods and more clearly indicate trends. Although IMS discloses adjusted Non-GAAP Free Cash Flow in order to give a full picture to investors of the operational performance of its business as seen by management, Non-GAAP Free Cash Flow is not prepared under a comprehensive set of accounting rules and is not a replacement for the more comprehensive information for investors included in IMS's U.S. GAAP results. The method IMS uses to prepare Non-GAAP Free Cash Flow differs in significant respects from U.S. GAAP and is likely to differ from the methods used by other companies. 2 Movements in deferred and accrued income taxes do not necessarily relate directly to current operations and therefore are excluded from Non-GAAP Free Cash Flow. 3 Non-GAAP Free Cash Flow is designed to only include IMS's share of net income from consolidated subsidiaries. 4 Tax benefits and expenses from stock-based compensation are excluded from Non-GAAP Free Cash Flow as they are considered to be financing activities. 5 Pension assets and liabilities and other inherently long-term assets and liabilities are not viewed as part of current operations and are therefore excluded from Non-GAAP Free Cash Flow. 6 Investments in capital assets and software are integral to the ongoing business and operations of the Company and are therefore included as part of Non-GAAP Free Cash Flow.
Data. Insights. Results.
Image Area Data. Insights. Results. Raymond James 26 th Annual Institutional Investors Conference March 2005 Safe Harbor Certain statements we make today are forward-looking within the meaning of US federal
More informationIMS Health Reports Second-Quarter 2014 Results. DANBURY, CT, July 24, 2014 IMS Health Holdings, Inc. ( IMS Health ) (NYSE:IMS), a
News For Immediate Release Contacts: Tor Constantino Tom Kinsley Media Relations Investor Relations +1.484.567.6732 +1.203.448.4691 tconstantino@us.imshealth.com tkinsley@imshealth.com IMS Health Reports
More informationIQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationNewell Rubbermaid Reports Third Quarter 2011 Results and Reaffirms Full Year 2011 Guidance
Newell Rubbermaid Reports Third Quarter 2011 Results and Reaffirms Full Year 2011 Guidance» Net Sales Growth of 5.8%; Core Sales Growth of 3.3%» Normalized EPS of $0.45» Announces Project Renewal: A Plan
More informationSYSCO REPORTS SECOND QUARTER FISCAL 2019 RESULTS. The Company delivered results in line with expectations
SYSCO REPORTS SECOND QUARTER FISCAL 2019 RESULTS The Company delivered results in line with expectations HOUSTON, February 4, 2019 - Sysco Corporation (NYSE: SYY) today announced financial results for
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE For media inquiries, contact: Eric Armstrong, Citrix Systems, Inc. (954) 267-2977 or eric.armstrong@citrix.com For investor inquiries, contact: Eduardo Fleites, Citrix Systems, Inc.
More informationAccenture Reports Strong First-Quarter Fiscal 2019 Results. -- Revenues increase 7% in U.S. dollars and 9.5% in local currency to $10.
Accenture Reports Strong First-Quarter Fiscal 2019 Results -- Revenues increase 7% in U.S. dollars and 9.5% in local currency to $10.6 billion -- -- EPS are $1.96, a 9% increase -- -- Operating income
More informationAccenture Reports Very Strong Fourth-Quarter and Full-Year Fiscal 2015 Results
Accenture Reports Very Strong Fourth-Quarter and Full-Year Fiscal 2015 Results -- Fourth-quarter revenues increase 1% in U.S. dollars and 12% in local currency, to $7.9 billion; quarterly EPS increase
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE For media inquiries, contact: Eric Armstrong, Citrix Systems, Inc. (954) 267-2977 or eric.armstrong@citrix.com For investor inquiries, contact: Eduardo Fleites, Citrix Systems, Inc.
More informationCPI Card Group Inc. Reports Fourth Quarter and Full Year 2016 Results
NEWS RELEASE CPI Card Group Inc. Reports Fourth Quarter and Full Year 2016 Results 3/1/2017 Q4 Net Sales of $67.4 million, Full Year 2016 Net Sales of $308.7 million Full Year Net Income from Continuing
More informationIntermolecular Announces Third Quarter 2017 Financial Results
Intermolecular Announces Third Quarter 2017 Financial Results SAN JOSE, Calif., November 2, 2017 -- Intermolecular, Inc. (NASDAQ: IMI) today reported results for its Third Quarter ended September 30, 2017.
More informationFOR IMMEDIATE RELEASE
Investor Contact Media Contact David Martin Kenneth Julian 717.612.5628 717.730.3683 damartin@harsco.com kjulian@harsco.com FOR IMMEDIATE RELEASE REPORTS SECOND QUARTER 2014 RESULTS Adjusted Operating
More informationResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2019
For investors For media Amy Wakeham Jayme Rubenstein +1 858-836-5000 +1 858-836-6798 investorrelations@resmed.com news@resmed.com ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2019
More informationIQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationWalgreens Boots Alliance Reports Fiscal 2019 First Quarter Results Delivers Double Digit Percentage Growth in Earnings Per Share (EPS)
Walgreens Boots Alliance Reports Fiscal 2019 First Quarter Results Delivers Double Digit Percentage Growth in Earnings Per Share (EPS) First quarter highlights, year-over-year Sales increased 9.9 percent
More informationAccenture Reports Fourth-Quarter and Full-Year Fiscal 2013 Results, With Record Annual Revenues, EPS, Operating Margin and New Bookings
Accenture Reports Fourth-Quarter and Full-Year Fiscal 2013 Results, With Record Annual Revenues, EPS, Margin and New Bookings -- Fourth-quarter revenues increase 4% in both U.S. dollars and local currency,
More informationECOLAB FOURTH QUARTER REPORTED DILUTED EPS $1.35 ADJUSTED DILUTED EPS $1.54, +12% 2019 ADJUSTED DILUTED EPS FORECAST $5.80 TO $6.
News Release Ecolab Inc. 1 Ecolab Place, St. Paul, Minnesota 55102 FOR IMMEDIATE RELEASE Michael J. Monahan (651) 250-2809 Andrew C. Hedberg (651) 250-2185 ECOLAB FOURTH QUARTER REPORTED DILUTED EPS $1.35
More informationIQVIA Reports First-Quarter 2018 Results and Raises Full-Year 2018 Revenue Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationLABCORP ANNOUNCES 2018 SECOND QUARTER RESULTS AND UPDATES 2018 GUIDANCE
FOR IMMEDIATE RELEASE Contact: Scott Frommer (investors) 336-436-5076 Investor@labcorp.com Pattie Kushner (media) 336-436-8263 Media@labcorp.com LABCORP ANNOUNCES 2018 SECOND QUARTER RESULTS AND UPDATES
More informationNewell Rubbermaid Announces Strong First Quarter Results
Newell Rubbermaid Announces Strong First Quarter Results» 4.7% Core Sales Growth and Normalized EPS of $0.36» 4.1% Net Sales Growth and Reported EPS of $0.20» Affirms 2015 Full Year Guidance» Expands Project
More informationWalgreens Boots Alliance Reports Fourth Quarter and Fiscal 2017 Results
October 25, 2017 Boots Alliance Reports Fourth Quarter and Fiscal 2017 Results Fourth quarter highlights GAAP diluted net earnings per share were $0.76, down 20.0 percent from the year-ago quarter due
More informationL I N C O L N E L E C T R I C H O L D I N G S, I N C Saint Clair Avenue Cleveland, Ohio U.S.A.
L I N C O L N E L E C T R I C H O L D I N G S, I N C. 22801 Saint Clair Avenue Cleveland, Ohio 44117 U.S.A. N E W S R E L E A S E LINCOLN ELECTRIC REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS Fourth
More informationResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2018
For investors For media Amy Wakeham Jayme Rubenstein O: 858-836-5000 O: 858-836-6798 investorrelations@resmed.com news@resmed.com ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2018
More informationAmeresco Reports Fourth Quarter and Full Year 2017 Financial Results
Contact: Media Relations Investor Relations FOR IMMEDIATE RELEASE CarolAnn Hibbard, 508.661.2264, news@ameresco.com John Granara, 508.661.2215, ir@ameresco.com Gary Dvorchak, CFA, The Blue Shirt Group,
More informationAccenture Reports Third-Quarter Fiscal 2009 Results. -- Company reports revenues of $5.15 billion and EPS of $
Accenture Reports Third-Quarter Fiscal 2009 Results -- Company reports revenues of $5.15 billion and EPS of $0.68 -- -- income is $732 million; operating margin expands to 14.2% -- -- Company delivers
More informationMcKESSON REPORTS FISCAL 2019 SECOND-QUARTER RESULTS
McKESSON REPORTS FISCAL 2019 SECOND-QUARTER RESULTS Revenues of $53.1 billion for the second quarter, up 2% year over year. Second-quarter GAAP earnings per diluted share from continuing operations of
More informationBrink's Reports First-Quarter Results
Contact: Investor Relations 804.289.9709 FOR IMMEDIATE RELEASE Brink's Reports First-Quarter Results North America Profits Double, South America Profits up 42% Acquisitions Contribute $51 Million Revenue
More informationMcKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS
McKESSON REPORTS FISCAL 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS Revenues of $48.7 billion for the fourth quarter and $198.5 billion for the full year, up 4% year-over-year. Fourth-quarter GAAP earnings
More informationAmeresco Reports Fourth Quarter and Full Year 2017 Financial Results
March 6, 2018 Ameresco Reports Fourth Quarter and Full Year 2017 Financial Results Full Year 2017 Financial Highlights (year over year): Revenues of $717.2 million, compared to $651.2 million, up 10% Net
More informationICG ANNOUNCES FOURTH QUARTER AND YEAR-END 2013 FINANCIAL RESULTS
FOR IMMEDIATE RELEASE Investor inquiries: Karen Greene ICG Investor Relations 610-727-6900 IR@icg.com ICG ANNOUNCES FOURTH QUARTER AND YEAR-END 2013 FINANCIAL RESULTS Company Exits Transformational Year
More informationECOLAB SECOND QUARTER REPORTED DILUTED EPS $1.20 ADJUSTED DILUTED EPS $1.27, +13% FULL YEAR 2018 ADJUSTED DILUTED EPS FORECAST $5.
News Release Ecolab Inc. 1 Ecolab Place, St. Paul, Minnesota 55102 FOR IMMEDIATE RELEASE Michael J. Monahan (651) 250-2809 Andrew C. Hedberg (651) 250-2185 ECOLAB SECOND QUARTER REPORTED DILUTED EPS $1.20
More informationDun & Bradstreet Reports Second Quarter 2016 Results; Announces Transactions to Partner Latin America and Benelux
August 1, 2016 Dun & Bradstreet Reports Second Quarter 2016 Results; Announces Transactions to Partner Latin America and Benelux Transactions Expected to be Accretive to 2016 and 2017 Operating Income
More informationResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2018
NEWS RELEASE ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2018 1/22/2018 Revenue increased 13% to $601.3 million; up 11% on a constant currency basis GAAP-diluted earnings per share
More informationNewell Rubbermaid Raises Full Year Guidance on Strong Second Quarter Results
Newell Rubbermaid Raises Full Year Guidance on Strong Second Quarter Results Jul 31, 2015 Second Quarter Executive Summary 5.1% Core Sales Growth and Normalized EPS of $0.64 3.9% Net Sales Growth and Reported
More informationCDW Reports Third Quarter 2015 Results
November 4, 2015 CDW Reports Third Quarter 2015 Results Record Third Quarter Net Sales, Adjusted EBITDA and Non-GAAP Net Income Per Share (Dollars in millions, except per share amounts) Three Months Ended
More informationCPI Card Group Inc. Reports Fourth Quarter and Full Year 2015 Results
CPI Card Group Inc. Reports Fourth Quarter and Full Year 2015 Results Fourth Quarter Net Sales of $93.6 million and Pro Forma Adjusted Diluted EPS of $0.16 Initiates Quarterly Dividend Announces 2016 Financial
More informationNewell Rubbermaid Reports Strong Fourth Quarter Results
Newell Rubbermaid Reports Strong Fourth Quarter Results - 6.2% Core Sales Growth; 4.4% Core Sales Growth excluding Venezuela - Normalized EPS $0.56, a 14.3% Increase versus Prior Year - Net Sales Growth
More informationIQVIA Reports Second-Quarter 2018 Results and Raises Full-Year 2018 Revenue and Profit Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationWalgreens Boots Alliance Reports Fourth Quarter and Fiscal 2016 Results
20 October 2016 Boots Alliance Reports Fourth Quarter and Fiscal 2016 Results Fourth quarter highlights GAAP diluted net earnings per share increase to $0.95 from $0.02 in the year-ago quarter; Adjusted
More information-- New bookings are $8.4 billion for fourth quarter and $28.8 billion for full year --
Accenture Reports Strong Fourth-Quarter and Full-Year Fiscal 2011 Results, With Record Annual Revenues, EPS, Margin, Free Cash Flow and New Bookings -- Fourth-quarter revenues increase 23% in U.S. dollars
More informationQuad/Graphics Reports Second Quarter and Year-to-Date 2017 Results
FOR IMMEDIATE RELEASE Quad/Graphics Reports Second Quarter and Year-to-Date 2017 Results Consistent Execution of Strategic Objectives Drives Increased Net Earnings and Margins SUSSEX, WI, August 1, 2017
More informationEnerNOC Reports Fourth Quarter and Full Year 2016 Results
March 14, 2017 EnerNOC Reports Fourth Quarter and Full Year 2016 Results BOSTON, March 14, 2017 (GLOBE NEWSWIRE) -- (Nasdaq:ENOC), a leading provider of demand response solutions and energy intelligence
More informationWaste Management Announces Fourth Quarter and Full-Year 2013 Earnings
Waste Management Announces Fourth Quarter and Full-Year 2013 Earnings February 18, 2014 Company sees strong cash generation in 2013 and expects continued strength in 2014 HOUSTON--(BUSINESS WIRE)--Feb.
More informationWalgreens Boots Alliance Reports Fiscal 2017 First Quarter Results
Walgreens Boots Alliance Reports Fiscal 2017 First Quarter Results First quarter highlights GAAP diluted net earnings per share decrease 4.0 percent from the year-ago quarter, to $0.97; Adjusted diluted
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationGenpact Reports 2008 Fourth Quarter and Full Year Results
For Immediate Release Genpact Reports 2008 Fourth Quarter and Full Year Results 2008 Full Year Revenues Grow 26%, Adjusted Income from Operations Increases 33% Gurgaon, India & New York, NY (February 18,
More informationSYSCO REPORTS FIRST QUARTER FISCAL 2018 RESULTS
For more information contact: Sysco Corporation 1390 Enclave Parkway Neil Russell Camilla Zuckero Houston, TX 77077 Investor Contact Media Contact T 281-584-1308 T 281-899-1839 SYSCO REPORTS FIRST QUARTER
More informationUnisys Announces 2017 Financial Results Exceeds or Achieves Full-Year Guidance on All Guidance Metrics
News Release Unisys Announces 2017 Financial Results Exceeds or Achieves Full-Year Guidance on All Guidance Metrics Company generates fourth-quarter 2017 total revenue of $747 million, representing growth
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE For media inquiries, contact: Eric Armstrong, Citrix Systems, Inc. (954) 267-2977 or eric.armstrong@citrix.com For investor inquiries, contact: Eduardo Fleites, Citrix Systems, Inc.
More information2018 Revenues Decreased 0.9%, or 0.7% on a Constant Currency Basis, in Line with Guidance
News Release Investor Relations: Sara Gubins, +1 646 654 8153 Media Relations: Laura Nelson, +1 203 563 2929 NIELSEN REPORTS 4 th QUARTER AND FULL YEAR 2018 RESULTS 2018 Revenues Decreased 0.9%, or 0.7%
More informationWind River Reports Fourth Quarter and Fiscal Year 2009 Results
CONTACT: Ian Halifax Anne Marie McCauley Wind River Wind River Chief Financial Officer Vice President, Investor Relations +1.510.749.2155 +1.510.749.2551 ian.halifax@windriver.com annemarie.mccauley@windriver.com
More informationO: O:
For investors For media Amy Wakeham Jayme Rubenstein O: 858-836-5000 O: 858-836-6798 investorrelations@resmed.com news@resmed.com ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2019
More informationCORELOGIC REPORTS FOURTH QUARTER AND FULL-YEAR 2016 FINANCIAL RESULTS
NEWS FOR IMMEDIATE RELEASE CORELOGIC REPORTS FOURTH QUARTER AND FULL-YEAR 2016 FINANCIAL RESULTS Full-Year 2016 Revenues, Operating Income, Operating Cash Flow, and Free Cash Flow Up Double-Digits From
More informationAccenture Reports Strong First-Quarter Fiscal 2018 Results. -- Revenues increase 12% in U.S. dollars and 10% in local currency to $9.
Accenture Reports Strong First-Quarter Fiscal 2018 Results -- Revenues increase 12% in U.S. dollars and 10% in local currency to $9.5 billion -- -- EPS are $1.79, a 13% increase -- -- Operating income
More informationAon Reports First Quarter 2018 Results
Investor Relations News from Aon Aon Reports First Quarter 2018 Results First Quarter Key Metrics as Reported under U.S. GAAP (1) Total revenue increased 30% to $3.1 billion, including an increase of $365
More informationPATTERSON COMPANIES REPORTS FISCAL 2018 FOURTH-QUARTER AND YEAR-END OPERATING RESULTS
PATTERSON COMPANIES REPORTS FISCAL FOURTH-QUARTER AND YEAR-END OPERATING RESULTS Fourth-quarter reported net sales totaled $1.4 billion. Fourth-quarter GAAP earnings from continuing operations of $0.23
More informationTE Connectivity Posts Strong Fiscal 2015 First Quarter Earnings. Sales Up 4 Percent; GAAP EPS Up 34 Percent; Adjusted EPS Up 20 Percent
TE Connectivity Posts Strong Fiscal 2015 First Quarter Earnings Sales Up 4 Percent; GAAP EPS Up 34 Percent; Adjusted EPS Up 20 Percent Company Announces Divestiture of Broadband Network Solutions for $3.0
More informationAccelerating the Shift to Digital
Fourth Quarter 2017 Earnings Supplement Accelerating the Shift to Digital February 7, 2018 2017 Cognizant Forward Looking Statements and Non-GAAP Financial Measures This earnings supplement includes statements
More informationFirst Data Reports Fourth Quarter and Full Year 2016 Financial Results
First Data Reports Fourth Quarter and Full Year 2016 Financial Results Q4 consolidated revenue of $2.9 billion, down 1 or up 1 excluding impacts from currency; $11.6 billion for full year 2016, up 1 or
More informationSalesforce Announces Record Second Quarter Fiscal 2019 Results Raises FY19 Revenue Guidance to $ Billion to $ Billion
John Cummings Salesforce Investor Relations 415-778-4188 jcummings@salesforce.com Gina Sheibley Salesforce Public Relations 917-297-8988 gsheibley@salesforce.com Salesforce Announces Record Second Quarter
More informationWalgreens Boots Alliance Reports Fiscal 2016 Third Quarter Results
Alliance Reports Fiscal 2016 Third Quarter Results GAAP third quarter net earnings attributable to Alliance per diluted share decrease 14.4 percent to $1.01 compared with the year-ago period; Adjusted
More informationGlobus Medical Reports Second Quarter 2016 Results
Globus Medical Reports Second Quarter Results AUDUBON, Pa., July 26, (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial
More informationAccenture Reports Strong Fourth-Quarter and Full-Year Fiscal 2008 Results
Accenture Reports Strong Fourth-Quarter and Full-Year Fiscal 2008 Results -- Quarterly revenues increase 17% in U.S. dollars and 10% in local currency, to $6.00 billion; Quarterly EPS up 35%, to $0.67
More informationFiscal 2018 Third Quarter Results. 28 June 2018
Fiscal 2018 Third Quarter Results 28 June 2018 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not
More informationCSC Delivers Revenue Growth and Sequential Commercial Margin Expansion in Second Quarter 2017
CSC Delivers Revenue Growth and Sequential Commercial Expansion in Second Quarter 2017 Q2 Earnings per Share from Continuing Operations of $0.10 includes Cumulative Impact of Certain Items of $(0.51) per
More informationAugust 7, Fellow Calix stockholders:
August 7, 2018 Fellow Calix stockholders: Our mission is to connect everyone and everything. Calix platforms empower our customers to build new business models, rapidly deploy new services and make the
More informationFOR IMMEDIATE RELEASE Michael J. Monahan (651)
News Release Ecolab Inc. 370 Wabasha Street North St. Paul, Minnesota 55102 FOR IMMEDIATE RELEASE Michael J. Monahan (651) 250-2809 ECOLAB REPORTED AND ADJUSTED FIRST QUARTER DILUTED EPS $0.77; ADJUSTED
More informationCLARCOR REPORTS RECORD FOURTH QUARTER DILUTED EARNINGS PER SHARE
FOR FURTHER INFORMATION CONTACT: David J. Fallon Chief Financial Officer Franklin, Tennessee 615-771-3100 FOR IMMEDIATE RELEASE WEDNESDAY, JANUARY 14, 2015 GAAP Financial Results: CLARCOR REPORTS RECORD
More informationAccenture Reports Strong Second-Quarter Fiscal 2017 Results. -- Revenues increase 5% in U.S. dollars and 6% in local currency to $8.
Accenture Reports Strong Second-Quarter Fiscal 2017 Results -- Revenues increase 5% in U.S. dollars and 6% in local currency to $8.3 billion -- -- EPS are $1.33; operating income increases 5% to $1.14
More informationTarget Reports Fourth Quarter and Full-Year 2016 Earnings
FOR IMMEDIATE RELEASE Contacts: John Hulbert, Investors, (612) 761-6627 Erin Conroy, Media, (612) 761-5928 Target Media Hotline, (612) 696-3400 Target Reports Fourth Quarter and Full-Year Earnings Fourth
More informationFor more information, contact: Brad Pogalz (952)
For more information, contact: Brad Pogalz (952) 887-3753 Donaldson Reports Fiscal 2018 First Quarter Earnings Sales increased 16.6 percent, with Engine up 24.9 percent and Industrial up 1.8 percent Full-year
More informationWEYCO REPORTS FOURTH QUARTER AND FULL YEAR 2015 RESULTS
WEYCO REPORTS FOURTH QUARTER AND FULL YEAR 2015 RESULTS (Milwaukee, Wisconsin---March 2, 2016) Weyco Group, Inc. (NASDAQ:WEYS) (the Company ) today announced financial results for the quarter and year
More informationWest Pharmaceutical Services, Inc. RBC Capital Markets Global Healthcare Conference
West Pharmaceutical Services, Inc. Eric M. Green, President & CEO William J. Federici, Senior Vice President & CFO February 21, 2018 Safe Harbor Statement Cautionary Statement Under the Private Securities
More informationAccenture Reports Strong Second-Quarter Fiscal 2018 Results. -- Revenues increase 15% in U.S. dollars and 10% in local currency to $9.
Accenture Reports Strong Second-Quarter Fiscal 2018 Results -- Revenues increase 15% in U.S. dollars and 10% in local currency to $9.6 billion -- -- EPS of $1.37 include a $0.21 charge related to U.S.
More informationNews from Xerox. Xerox Reports Fourth-Quarter Earnings
News from Xerox For Immediate Release Xerox Corporation 45 Glover Avenue P.O. Box 4505 Norwalk, CT 06856-4505 tel +1-203-968-3000 Xerox Reports Fourth-Quarter Earnings GAAP EPS from continuing operations
More informationHorizon Global Reports Financial Results for the First Quarter 2017; Raises Full-Year 2017 Earnings Per Share Guidance and Announces Share Repurchase
Published on Horizon Global Investor Center (http://investors.horizonglobal.com) on 5/3/17 5:00 pm EDT Horizon Global Reports Financial Results for the First Quarter 2017; Raises Full-Year 2017 Earnings
More informationCardinal Health Reports Fiscal 2010 Results, Raises Fiscal 2011 Outlook
Cardinal Health Reports Fiscal 2010 Results, Raises Fiscal 2011 Outlook - Full-year revenue increases 3 percent to $99 billion - Fiscal 2010 diluted earnings per share from continuing operations of $1.62,
More informationEPAM Reports Results for Third Quarter 2018
EPAM Reports Results for Third Quarter November 1, Third quarter revenues of $468.2 million, up 24.0% year-over-year GAAP Diluted EPS of $1.15 for the third quarter Non-GAAP Diluted EPS of $1.17 for the
More informationPage 1/12. Yum China Reports Fourth Quarter and Full Year 2017 Results. February 7, :30 PM ET
Yum China Reports Fourth Quarter and Full Year 2017 Results February 7, 2018 4:30 PM ET SHANGHAI, Feb. 7, 2018 /PRNewswire/ -- (the "Company" or "Yum China") (NYSE: YUMC) today reported unaudited results
More informationMcKesson Corporation Q2 Fiscal 2019 Financial Performance. Financial Results and Company Highlights October 25, 2018
McKesson Corporation Q2 Fiscal 2019 Financial Performance Financial Results and Company Highlights October 25, 2018 Forward-Looking Statements Some of the information in this presentation is not historical
More informationMcKESSON REPORTS FISCAL 2018 SECOND-QUARTER RESULTS
McKESSON REPORTS FISCAL 2018 SECOND-QUARTER RESULTS Revenues of $52.1 billion for the second quarter, up 4% year-over-year. Second-quarter GAAP earnings per diluted share from continuing operations of
More informationCOGNIZANT REPORTS SECOND QUARTER 2018 RESULTS
Exhibit 99.1 Glenpointe Centre West 500 Frank W. Burr Blvd. Teaneck, NJ 07666 COGNIZANT REPORTS SECOND QUARTER 2018 RESULTS Second quarter 2018 revenue of $4.01 billion, up 9.2% over 2017 Declares quarterly
More information(415) (415) LEVI STRAUSS & CO. ANNOUNCES FOURTH QUARTER & FISCAL YEAR 2017 FINANCIAL RESULTS
FOR IMMEDIATE RELEASE Investor Contact: Edelita Tichepco Media Contact: Avery Vaught Levi Strauss & Co. Levi Strauss & Co. (415) 501-1953 (415) 501-2214 Investor-relations@levi.com newsmediarequests@levi.com
More informationVisa Inc. Posts Solid Fiscal Fourth Quarter and Full-Year 2009 Earnings Results and Authorizes a
Visa Inc. Posts Solid Fiscal Fourth Quarter and Full-Year 2009 Earnings Results and Authorizes a $1 Billion Share Repurchase Plan Adjusted quarterly net income of $552 million or $0.74 per diluted class
More informationAccenture Reports Strong Second-Quarter Fiscal 2016 Results and Raises Revenue and EPS Outlook for Fiscal 2016
Accenture Reports Strong Second-Quarter Fiscal 2016 Results and Raises Revenue and EPS Outlook for Fiscal 2016 -- Revenues increase 6% in U.S. dollars and 12% in local currency to $7.9 billion -- -- EPS
More information23/05/2018 The TJX Companies, Inc. Reports Above-Plan Q1 FY19 Comp Sales Growth of 3% and Exceeds EPS Expectations; Updates Full-
154.126.80.126 The TJX Companies, Inc. Reports Above-Plan Q1 FY19 Comp Sales Growth of 3% and Exceeds EPS Expectations; Updates Full-Year Guidance to Reflect Strong Q1 Results Net sales increased 12% to
More informationSealed Air Reports Fourth Quarter and Full Year 2018 Results
Exhibit 99.1 Sealed Air Corporation 2415 Cascade Pointe Blvd. Charlotte, NC 28208 For release: February 7, 2019 Sealed Air Reports Fourth Quarter and Full Year 2018 Results Solid year-over-year sales and
More informationAngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
July 18, 2017 AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results Company posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance Q4 net sales of
More informationStaples, Inc. Announces First Quarter 2017 Performance
Media Contact: Bill Durling 508-253-2882 Investor Contact: Chris Powers/Scott Tilghman 508-253-4632/1487 Staples, Inc. Announces First Quarter 2017 Performance FRAMINGHAM, Mass., May 16, 2017 Staples,
More informationDOUBLE-DIGIT SALES GROWTH DRIVES STRONG FOURTH QUARTER RESULTS FOR EDWARDS LIFESCIENCES
Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amanda C. Fowler, 949-250-5070 Investor
More informationACTUANT REPORTS THIRD QUARTER RESULTS; UPDATES FISCAL 2018 GUIDANCE
For Immediate Release N86 W12500 Westbrook Crossing Menomonee Falls, WI 53051 Contact: Karen Bauer Communications & Investor Relations Leader 262-293-1562 ACTUANT REPORTS THIRD QUARTER RESULTS; UPDATES
More informationAdtalem Global Education Announces Fourth Quarter and Full Year Fiscal 2018 Results
News Release Investor Contact: Beth Coronelli Beth.Coronelli@Adtalem.com 630-353-9035 Media Contact: Ernie Gibble Ernie.Gibble@Adtalem.com 630-353-9920 Adtalem Global Education Announces Fourth Quarter
More informationAmerican Eagle Outfitters Reports 2015 Annual EPS Growth of 73% to $1.09
NEWS RELEASE American Eagle Outfitters Reports 2015 Annual EPS Growth of 73% to $1.09 3/2/2016 Fourth Quarter EPS Rises to $0.42 PITTSBURGH--(BUSINESS WIRE)-- American Eagle Outfitters, Inc. (NYSE:AEO)
More informationVF REPORTS 2016 FOURTH QUARTER AND FULL YEAR RESULTS; PROVIDES OUTLOOK FOR 2017
VF REPORTS 2016 FOURTH QUARTER AND FULL YEAR RESULTS; PROVIDES OUTLOOK FOR 2017 2016 revenue from continuing operations in line with 2015 at $12 billion (up 1 percent currency neutral); 2016 international
More informationDiplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance
NEWS RELEASE Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance 2/26/2018 4th Quarter Revenue of $1,155 Million, Net Income Attributable to Diplomat of $6.5 Million,
More informationNCR Announces Fourth Quarter and Full Year 2018 Results
NCR Corporation Logo NCR Announces Fourth Quarter and Full Year 2018 Results February 7, 2019 ATLANTA--(BUSINESS WIRE)--Feb. 7, 2019-- NCR Corporation (NYSE: NCR) reported financial results today for the
More informationNIELSEN REPORTS 2nd QUARTER 2018 RESULTS Conducting a Strategic Review of Buy Segment
News Release Investor Relations: Sara Gubins, +1 646 654 8153 Media Relations: Laura Nelson, +1 203 563 2929 NIELSEN REPORTS 2nd QUARTER 2018 RESULTS Conducting a Strategic Review of Buy Segment New York,
More informationInvestor Contact: Will Gabrielski Vice President, Investor Relations
Press Release Investor Contact: Will Gabrielski Vice President, Investor Relations 213.593.8208 William.Gabrielski@aecom.com Media Contact: Brendan Ranson-Walsh Vice President, Global Communications &
More informationNews from Aon Aon Reports Fourth Quarter and Full Year 2018 Results Fourth Quarter Key Metrics as Reported Under U.S. GAAP(1)
Investor Relations News from Aon Aon Reports Fourth Quarter and Full Year Results Fourth Quarter Key Metrics as Reported Under U.S. GAAP (1) Total revenue decreased 5 to $2.8 billion, including a decrease
More informationSalesforce Announces Record Third Quarter Revenue, Raises Full Year Fiscal 2018 Revenue Guidance
John Cummings Salesforce Investor Relations 415-778-4188 jcummings@salesforce.com Gina Sheibley Salesforce Public Relations 917-297-8988 gsheibley@salesforce.com Salesforce Announces Record Third Quarter
More information